- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00455988
Developement of Questionnaire to Evaluate a Regularity of Lifestyle in Type 2 Diabetic Patients
April 3, 2007 updated by: Eulji University Hospital
In order to manage of type 2 diabetic patients with irregular lifestyle, developement of an appropriate questionnaire to evaluate a regularity of lifestyle is necessary.
Study Overview
Status
Unknown
Conditions
Detailed Description
We have a plan to perform the seven day's records and the questionnaires which is necessary to type 2 diabetic patients for the initial step.
Next, we will revise a questionnaire with professional advices for several times.
Finally we will test a reliability with a final version as form of multisite based study and will confirm a questionnaire for a regularity of lifestyle in type 2 diabetes.
Study Type
Observational
Enrollment
360
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 139-711
- Recruiting
- Eulji University Hospital
-
Contact:
- Song Yi Back
- Phone Number: 82-2-970-8459
- Email: glorialin@hanmail.net
-
Contact:
- Ji Sun Min
- Phone Number: 82-2-970-8459
-
Principal Investigator:
- Kyung Wan Min, MD., PhD
-
Sub-Investigator:
- Kyung Ah Han, MD., PhD
-
Sub-Investigator:
- Hyo Jeong Kim, MD., PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 2 diabetic patients
Exclusion Criteria:
- Type 1 diabetic patients, gestational DM patients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kyung Wan Min, MD., PhD, Eulji University Hospital Diabetes Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Study Completion (Anticipated)
December 1, 2007
Study Registration Dates
First Submitted
April 3, 2007
First Submitted That Met QC Criteria
April 3, 2007
First Posted (Estimate)
April 4, 2007
Study Record Updates
Last Update Posted (Estimate)
April 4, 2007
Last Update Submitted That Met QC Criteria
April 3, 2007
Last Verified
April 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Questionnaire06-27-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted